SCHEMBL5584495

SCHEMBL5584495

Oc1ccccc1C=Cc1nc2ccccc2s1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 3/20 0.74
MAPT P10636 9/20 0.54
RAB9A P51151 7/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
TDP1 Q9NUW8 1/20 0.54
KDM4E B2RXH2 5/20 0.53
ALDH1A1 P00352 4/20 0.53
POLB P06746 2/20 0.53
GAA P10253 2/20 0.53
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
APP P05067 1/20 0.51
INSR P06213 1/20 0.51
NCOA1 Q15788 1/20 0.51
ECE2 P0DPD6 2/20 0.50
NPC1 O15118 5/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14571513 1.00 SNCA (0.74) SNCAMAPTRAB9AMEN1KMT2A
SCHEMBL10619184 0.88 SNCA (0.65) SNCAMAPTRAB9AMEN1KMT2A
SCHEMBL9514565 0.83 SNCA (0.76) SNCAMAPTRAB9AMEN1KMT2A
SCHEMBL9514559 0.83 SNCA (0.76) SNCAMAPTRAB9AMEN1KMT2A
SCHEMBL8718231 0.81 SNCA (0.57) SNCAMAPTRAB9AMEN1KMT2A
SCHEMBL537900 0.81 SNCA (0.57) SNCAMAPTRAB9AMEN1KMT2A
SCHEMBL3447907 0.81 SNCA (0.57) SNCAMAPTRAB9AMEN1KMT2A
SCHEMBL8034150 0.81 SNCA (0.78) SNCAMAPTRAB9AMEN1KMT2A
SCHEMBL8718230 0.81 SNCA (0.57) SNCAMAPTRAB9AMEN1KMT2A
SCHEMBL6491431 0.81 MEN1 (0.66) SNCAMAPTRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A SNCA 1374/4885MAPT 949/4885RAB9A 2487/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A SNCA 1374/4885MAPT 949/4885RAB9A 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.